← Back to Clinical Trials
Recruiting NCT06933758

NCT06933758 Temple Health Chest Initiative (THCI 2.0)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06933758
Status Recruiting
Phase
Sponsor Temple University
Condition Chronic Obstructive Pulmonary Disease (COPD)
Study Type OBSERVATIONAL
Enrollment 1,000 participants
Start Date 2025-02-28
Primary Completion 2026-05-31

Eligibility & Interventions

Sex All sexes
Min Age 50 Years
Max Age 80 Years
Study Type OBSERVATIONAL
Interventions
Determine COPD prevalence utilizing spirometry along with CT scans and symptom assessments in the THCI lung cancer screening populatio

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,000 participants in total. It began in 2025-02-28 with a primary completion date of 2026-05-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Chronic obstructive pulmonary disease is highly prevalent globally, with considerable morbidity and mortality associated. In the US, it is the 4th leading cause of death, as well as contributing to significant costs on healthcare utilization including hospitalization. Population-based screening for COPD has not been recommended by the US Preventative Services Task Force (USPSTF). However, LDCT screening for lung cancer in patients aged 50- 80 with ≥ 20 pack year smoking has been shown to improve survival. COPD is highly prevalent within LCS programs, with estimated rates of obstructive lung function of up to 59% and evidence of emphysema on CT scan in around 70%.

Eligibility Criteria

Inclusion Criteria: * 50 to 80 years old * Screened for early lung cancer using low dose CT imaging Exclusion Criteria: * Under 50; over 80 years old * No lung cancer screening

Contact & Investigator

Central Contact

Lauren Miller, BS

✉ lauren.e.miller@temple.edu

📞 215-707-4821

Principal Investigator

Gerard Criner, MD

PRINCIPAL INVESTIGATOR

Temple University

Frequently Asked Questions

Who can join the NCT06933758 clinical trial?

This trial is open to participants of all sexes, aged 50 Years or older, up to 80 Years, studying Chronic Obstructive Pulmonary Disease (COPD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06933758 currently recruiting?

Yes, NCT06933758 is actively recruiting participants. Contact the research team at lauren.e.miller@temple.edu for enrollment information.

Where is the NCT06933758 trial being conducted?

This trial is being conducted at Philadelphia, United States.

Who is sponsoring the NCT06933758 clinical trial?

NCT06933758 is sponsored by Temple University. The principal investigator is Gerard Criner, MD at Temple University. The trial plans to enroll 1,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology